101403-25-2

Basic information

• Product Name: ((R)-5-METHOXY-1,2,3,4-TETRAHYDRO-NAPHTHALEN-2-YL)-PROPYL-AMINE HYDROCHLORIDE
• Synonyms: ((R)-5-METHOXY-1,2,3,4-TETRAHYDRO-NAPHTHALEN-2-YL)-PROPYL-AMINE HYDROCHLORIDE;(R)-5-METHOXY-N-PROPYL-2-AMINOTETRALINE HYDROCHLORIDE;2-NAPHTHALENAMINE, 1,2,3,4-TETRAHYDRO-5-METHOXY-N-PROPYL-, HYDROCHLORIDE, (2R)-;(+)-5-Methoxy-N-propyl-2-aminotetralin;(2R)-1,2,3,4-Tetrahydro-5-methoxy-N-propyl-2-naphthalenamine
• CAS NO: 101403-25-2
• Molecular Formula: C₁₄H₂₁NO
• Molecular Weight: 219.32
• Mol File: 101403-25-2.mol
• Article Data: 7

Chemical Properties

• Appearance: /
• CAS DataBase Reference: ((R)-5-METHOXY-1,2,3,4-TETRAHYDRO-NAPHTHALEN-2-YL)-PROPYL-AMINE HYDROCHLORIDE(CAS DataBase Reference)
• NIST Chemistry Reference: ((R)-5-METHOXY-1,2,3,4-TETRAHYDRO-NAPHTHALEN-2-YL)-PROPYL-AMINE HYDROCHLORIDE(101403-25-2)
• EPA Substance Registry System: ((R)-5-METHOXY-1,2,3,4-TETRAHYDRO-NAPHTHALEN-2-YL)-PROPYL-AMINE HYDROCHLORIDE(101403-25-2)

Safety Data

• Hazardous Substances Data: 101403-25-2(Hazardous Substances Data)

Usage

Description

((R)-5-METHOXY-1,2,3,4-TETRAHYDRO-NAPHTHALEN-2-YL)-PROPYL-AMINE HYDROCHLORIDE is a chemical compound with the molecular formula C15H23NO.HCl. It is a white crystalline powder that is used in pharmaceutical research as a potential treatment for various neurological and psychiatric disorders. ((R)-5-METHOXY-1,2,3,4-TETRAHYDRO-NAPHTHALEN-2-YL)-PROPYL-AMINE HYDROCHLORIDE acts as a selective serotonin reuptake inhibitor (SSRI), which means it helps to increase the levels of serotonin in the brain, thereby regulating mood and emotions.

Uses

Used in Pharmaceutical Research:
((R)-5-METHOXY-1,2,3,4-TETRAHYDRO-NAPHTHALEN-2-YL)-PROPYL-AMINE HYDROCHLORIDE is used as a research compound for the development of potential treatments for neurological and psychiatric disorders. Its role as an SSRI makes it a candidate for therapeutic effects in conditions such as depression, anxiety, and obsessive-compulsive disorder.
Used in Treatment of Neurological Disorders:
In the field of neurology, ((R)-5-METHOXY-1,2,3,4-TETRAHYDRO-NAPHTHALEN-2-YL)-PROPYL-AMINE HYDROCHLORIDE is used as a potential treatment for depression, leveraging its ability to increase serotonin levels in the brain and regulate mood.
Used in Treatment of Psychiatric Disorders:
In psychiatry, ((R)-5-METHOXY-1,2,3,4-TETRAHYDRO-NAPHTHALEN-2-YL)-PROPYL-AMINE HYDROCHLORIDE is used as a potential treatment for anxiety and obsessive-compulsive disorder, due to its influence on serotonin levels and emotional regulation.
Used in Pain Management:
((R)-5-METHOXY-1,2,3,4-TETRAHYDRO-NAPHTHALEN-2-YL)-PROPYL-AMINE HYDROCHLORIDE may also have applications in the treatment of pain, although the specific reasons and mechanisms would require further research and clinical trials to confirm.
Used in Addiction Treatment:
Additionally, ((R)-5-METHOXY-1,2,3,4-TETRAHYDRO-NAPHTHALEN-2-YL)-PROPYL-AMINE HYDROCHLORIDE is being investigated for its potential use in addiction treatment, suggesting that it may have properties that could assist in managing addictive behaviors, although more research would be needed to establish its efficacy and safety in this context.

Upstream product

• 3904-24-3 (5-methoxy-1,2,3,4-tetrahydronaphthalen-2-yl)propylamine hydrochloride 
• 58349-20-5 (R)-(+)-2-(N-benzylamino)-5-methoxytetralin 
• 802294-64-0 propionic acid 
• 101403-23-0 (R)-2-<(benzyl)propylamino>-5-methoxytetralin 
• 78598-91-1 2-(N-propylamino)-5-methoxytetraline 
• 244239-68-7 (R)-N-(5-methoxy-1,2,3,4-tetrahydronaphthalen-2-yl)propionamide 
• 105086-92-8 (R)-5-methoxy-2-aminotetralin 
• 32940-15-1 5-methoxy-2-tetralone 
• 136247-07-9 2-(N-benzylamino)-5-methoxytetralin 
• 107-10-8 propylamine 

Downstream Products

• 136247-11-5 N-((R)-5-Methoxy-1,2,3,4-tetrahydro-naphthalen-2-yl)-2-(4-nitro-phenyl)-N-propyl-acetamide 
• 165950-84-5 (R)-(+)-5-hydroxy-2-(n-propylamino)tetralin hydrobromide 
• 129388-77-8 (R)-(+)-2--5-hydroxytetralin 
• 136316-05-7 (R)-(+)-2--5-methoxytetralin 
• 99755-59-6 rotigotine 
• 165950-84-5 (S)-1,2,3,4-tetrahydro-5-hydroxy-N-propyl-naphthalen-2-ammonium hydrobromide 
• 125572-93-2 rotigotine hydrochloride 
• 78598-91-1 2-(N-propylamino)-5-methoxytetraline 
• 1352917-65-7 (S)-1,2,3,4-tetrahydro-5-methoxy-N-propyl-naphthalen-2-ammonium (R)-2-methoxy-2-phenylacetate 
• 1352917-66-8 (S)-1,2,3,4-tetrahydro-5-methoxy-N-propyl-naphthalen-2-ammonium (R)-2-(2-chlorophenyl)-2-hydroxyacetate 
• 1352917-67-9 (S)-1,2,3,4-tetrahydro-5-methoxy-N-propyl-naphthalen-2-ammonium (S)-2-hydroxy-3-phenylpropionate 
• 93601-86-6 (S)-(-)-(5-methoxy-1,2,3,4-tetrahydronaphthalen-2-yl)propylamine hydrochloride 
• 1352917-68-0 (S)-1,2,3,4-tetrahydro-5-methoxy-N-propyl-naphthalen-2-ammonium (S)-2-methoxy-2-phenylacetate 
• 3904-24-3 (5-methoxy-1,2,3,4-tetrahydronaphthalen-2-yl)propylamine hydrochloride 

Relevant articles and documents

Synthesis of Pharmaceutically Relevant 2-Aminotetralin and 3-Aminochroman Derivatives via Enzymatic Reductive Amination

2-Aminotetralin and 3-aminochroman derivatives are key structural motifs present in a wide range of pharmaceutically important molecules. Herein, we report an effective biocatalytic approach towards these molecules through the enantioselective reductive coupling of 2-tetralones and 3-chromanones with a diverse range of primary amine partners. Metagenomic imine reductases (IREDs) were employed as the biocatalysts, obtaining high yields and enantiocomplementary selectivity for >15 examples at preparative scale, including the precursors to Ebalzotan, Robalzotan, Alnespirone and 5-OH-DPAT. We also present a convergent chemo-enzymatic total synthesis of the Parkinson's disease therapy Rotigotine in 63 % overall yield and 92 % ee.

Synthesis and pharmacology of the enantiomers of the potential atypical antipsychotic agents 5-OMe-BPAT and 5-OMe-(2,6-di-OMe)-BPAT

The optically pure enantiomers of the potential atypical antipsychotic agents 5-methoxy-2-[N-(2-benzamidoethyl)-N-n-propylamino]tetralin (5-OMe-BPAT, 5) and 5-methoxy-2-{N-[2-(2,6-dimethoxy)benzamidoethyl]-N-n-propylamino}tetralin [5-OMe-(2,6-di-OMe)-BPAT

Fluorescent Probes for Dopamine Receptors: Synthesis and Characterization of Fluorescein and 7-Nitrobenz-2-oxa-1,3-diazol-4-yl Conjugates of D-1 and D-2 Receptor Ligands

Fluorescent probes have been designed and developed for dopamine D-1 and D-2 receptors.Fluorescein and/or NBD (7-nitrobenz-2-oxa-1,3-diazol-4-yl)derivatives of PPHT (D-2 agonist), spiperone (D-2 antagonist), SKF 38393 (D-1 agonist), and SKF 83566 (D-1 antagonist) were synthesized via their amino-functionalized analogues and all ligands were pharmacologically evaluated by measuring their ability to displace SCH 23390 and 3H)spiperone from D-1 and D-2 receptor sites in caudate putamen of monkeys (Macaca fascicularis).The fluorescein derivatives of PPHT andSKF 83566 and the NBD derivatives of spiperone and SKF 83566 retained the high affinity and selectivity of parent ligands.The NBD derivatives of PPHT showed higher D-2 receptor affinity and selectivity than their parent ligands.The enantiomers of the fluorescent derivatives of PPHT were also synthesized and were found to exhibit stereoselectivity in binding to the D-2 receptor, with the S enantiomers having a considerably higher affinity than their R analogues.In contrast to these results, the fluorescein derivative of SKF 38393 showed only a low affinity for the D-1 receptor.These fluorescein- and NBD-coupled D-1 and D-2 receptor ligands have considerable significance as potential probes in the study of distribution of the receptors at the cellular/subcellular level and of their mobility in membranes in normal/diseased states by use of fluorescence microscopic and fluorescence photobleaching recovery techniques, respectively.The development of these novel fluorescent probes should also provide new leads for the design and synthesis of additional fluorescent ligands with better fluorescent properties and/or higher affinity/selectivity for the DA receptors.